These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 37671615)

  • 21. Neuropathology and molecular diagnosis of Synucleinopathies.
    Koga S; Sekiya H; Kondru N; Ross OA; Dickson DW
    Mol Neurodegener; 2021 Dec; 16(1):83. PubMed ID: 34922583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.
    Zhang W; Wang T; Pei Z; Miller DS; Wu X; Block ML; Wilson B; Zhang W; Zhou Y; Hong JS; Zhang J
    FASEB J; 2005 Apr; 19(6):533-42. PubMed ID: 15791003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.
    Dijkstra AA; Voorn P; Berendse HW; Groenewegen HJ; ; Rozemuller AJ; van de Berg WD
    Mov Disord; 2014 Sep; 29(10):1244-51. PubMed ID: 24996051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy.
    Joers V; Murray BC; McLaughlin C; Oliver D; Staley HE; Coronado J; Achat-Mendes C; Golshani S; Kelly SD; Goodson M; Lee D; Manfredsson FP; Moore Ii BM; Tansey MG
    J Neuroinflammation; 2024 Sep; 21(1):240. PubMed ID: 39334169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A breakdown in microglial metabolic reprogramming causes internalization dysfunction of α-synuclein in a mouse model of Parkinson's disease.
    Lu J; Wang C; Cheng X; Wang R; Yan X; He P; Chen H; Yu Z
    J Neuroinflammation; 2022 May; 19(1):113. PubMed ID: 35599331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synucleinopathies.
    Martinez-Valbuena I; Amat-Villegas I; Valenti-Azcarate R; Carmona-Abellan MDM; Marcilla I; Tuñon MT; Luquin MR
    Acta Neuropathol; 2018 Jun; 135(6):877-886. PubMed ID: 29536165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential Modes of Intercellular α-Synuclein Transmission.
    Valdinocci D; Radford RA; Siow SM; Chung RS; Pountney DL
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initiation and progression of α-synuclein pathology in Parkinson's disease.
    Tofaris GK
    Cell Mol Life Sci; 2022 Mar; 79(4):210. PubMed ID: 35347432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies.
    Poggiolini I; Erskine D; Vaikath NN; Ponraj J; Mansour S; Morris CM; El-Agnaf OMA
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34072869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
    Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
    Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aggregation and beyond: alpha-synuclein-based biomarkers in synucleinopathies.
    Chopra A; Outeiro TF
    Brain; 2024 Jan; 147(1):81-90. PubMed ID: 37526295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy.
    Schaser AJ; Stackhouse TL; Weston LJ; Kerstein PC; Osterberg VR; López CS; Dickson DW; Luk KC; Meshul CK; Woltjer RL; Unni VK
    Acta Neuropathol Commun; 2020 Aug; 8(1):150. PubMed ID: 32859276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LRP1 is a neuronal receptor for α-synuclein uptake and spread.
    Chen K; Martens YA; Meneses A; Ryu DH; Lu W; Raulin AC; Li F; Zhao J; Chen Y; Jin Y; Linares C; Goodwin M; Li Y; Liu CC; Kanekiyo T; Holtzman DM; Golde TE; Bu G; Zhao N
    Mol Neurodegener; 2022 Sep; 17(1):57. PubMed ID: 36056345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies.
    Codolo G; Plotegher N; Pozzobon T; Brucale M; Tessari I; Bubacco L; de Bernard M
    PLoS One; 2013; 8(1):e55375. PubMed ID: 23383169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's disease.
    Er S; Airavaara M
    Biochem Soc Trans; 2023 Feb; 51(1):245-257. PubMed ID: 36794783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activated microglia facilitate the transmission of α-synuclein in Parkinson's disease.
    Zheng T; Zhang Z
    Neurochem Int; 2021 Sep; 148():105094. PubMed ID: 34097990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Involvement of autophagic protein DEF8 in Lewy bodies.
    Tanaka MT; Miki Y; Bettencourt C; Ozaki T; Tanji K; Mori F; Kakita A; Wakabayashi K
    Biochem Biophys Res Commun; 2022 Oct; 623():170-175. PubMed ID: 35921708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parkinson's disease-derived α-synuclein assemblies combined with chronic-type inflammatory cues promote a neurotoxic microglial phenotype.
    Yildirim-Balatan C; Fenyi A; Besnault P; Gomez L; Sepulveda-Diaz JE; Michel PP; Melki R; Hunot S
    J Neuroinflammation; 2024 Feb; 21(1):54. PubMed ID: 38383421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.